Benchmark Raises PT on Equinix (EQIX) to $200; Outlook Robust
Get Alerts EQIX Hot Sheet
Price: $815.31 --0%
Rating Summary:
27 Buy, 13 Hold, 0 Sell
Rating Trend: Down
Today's Overall Ratings:
Up: 10 | Down: 9 | New: 10
Rating Summary:
27 Buy, 13 Hold, 0 Sell
Rating Trend: Down
Today's Overall Ratings:
Up: 10 | Down: 9 | New: 10
Join SI Premium – FREE
Benchmark maintains a 'Buy' on Equinix (NASDAQ: EQIX) price target of $200.00 (from $170.00).
Analyst, Clayton F. Moran, said, "The company reiterated its forecast to achieve free cash flow next year and its goal to reach $3 billion in annual revenue by 2015 with an EBITDA margin around 50%. Equinix did not say anything meaningful about 2Q12 and 2012 guidance or the possible REIT conversion. We do not view this event as a positive catalyst for the stock. But we do believe the stock will go higher over the next 12 months and raise our price target to $200 per share. Our new target is based on 14x 2012E EBITDA, comparable to peers Digital Realty and Telecity."
For an analyst ratings summary and ratings history on Equinix click here. For more ratings news on Equinix click here.
Shares of Equinix closed at $171.92 yesterday.
Analyst, Clayton F. Moran, said, "The company reiterated its forecast to achieve free cash flow next year and its goal to reach $3 billion in annual revenue by 2015 with an EBITDA margin around 50%. Equinix did not say anything meaningful about 2Q12 and 2012 guidance or the possible REIT conversion. We do not view this event as a positive catalyst for the stock. But we do believe the stock will go higher over the next 12 months and raise our price target to $200 per share. Our new target is based on 14x 2012E EBITDA, comparable to peers Digital Realty and Telecity."
For an analyst ratings summary and ratings history on Equinix click here. For more ratings news on Equinix click here.
Shares of Equinix closed at $171.92 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Downgrades Munich Re (MUV2:GR) (MURGY) to Reduce, 'dividend yield remains relatively low'
- Morgan Stanley Downgrades Sanbio Co Ltd. (4592:JP) (SNBIF) to Equalweight
- Mereo BipPharma Group (MREO) PT Raised to $6 at Needham on increased 'launch expectations for setrusumab in OI'
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!